Frontiers in cellular and infection microbiology · 2026
Characteristics and outcomes of patients treated with tigecycline for MDR gram-negative infections: a retrospective cohort study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alowais Shuroug A, Aldairem Atheer, Bin Saleh Khalid, Alsowaida Yazed S, Alharbi Muhannad Musaad, Wali Haytham A, Almangour Thamer A
Аннотация
INTRODUCTION: Multidrug-resistant (MDR) gram-negative pathogens pose a major therapeutic challenge, particularly in settings with limited antimicrobial options. Tigecycline is frequently used as salvage therapy. However, evidence regarding the optimal tigecycline regimen, whether used as monotherapy or in combination, remains uncertain. This study aimed to describe the characteristics, clinical, and microbiological outcomes of these cases.
METHODS: Retrospective, single-center study of adult hospitalized patients treated with tigecycline for MDR Acinetobacter baumannii, extended-spectrum β-lactamase (ESBL)-producing Escherichia coli, and ESBL- or Carbapenem-Resistant Enterobacterales Klebsiella pneumoniae. Patients were categorized into tigecycline monotherapy or combination therapy groups. The primary outcomes were clinical success and 30-day mortality. Multivariable logistic regression was used to identify predictors of outcomes. A sensitivity analysis excluding bloodstream and urinary tract infections was performed due to pharmacokinetic limitations of tigecycline.
RESULTS: Two hundred eighty were included; 116 (41.4%) received tigecycline monotherapy and 164 (58.6%) received combination therapy. Patients receiving combination therapy had higher illness severity and higher intensive care unit admissions. Overall clinical success was achieved in 53.2% of patients with a higher rate in the monotherapy group (64.7%, p = 0.001), and 30-day mortality was 26.1%. After adjustment, tigecycline monotherapy was not independently associated with clinical success or mortality. Sensitivity analyses excluding bloodstream and urinary tract infections showed consistent results.
CONCLUSION: In this real-world cohort of severely ill patients with MDR gram-negative infections, no outcome advantage was observed with tigecycline combination therapy after adjustment. Clinical outcomes were primarily driven by illness severity and infection characteristics rather than treatment strategy.
METHODS: Retrospective, single-center study of adult hospitalized patients treated with tigecycline for MDR Acinetobacter baumannii, extended-spectrum β-lactamase (ESBL)-producing Escherichia coli, and ESBL- or Carbapenem-Resistant Enterobacterales Klebsiella pneumoniae. Patients were categorized into tigecycline monotherapy or combination therapy groups. The primary outcomes were clinical success and 30-day mortality. Multivariable logistic regression was used to identify predictors of outcomes. A sensitivity analysis excluding bloodstream and urinary tract infections was performed due to pharmacokinetic limitations of tigecycline.
RESULTS: Two hundred eighty were included; 116 (41.4%) received tigecycline monotherapy and 164 (58.6%) received combination therapy. Patients receiving combination therapy had higher illness severity and higher intensive care unit admissions. Overall clinical success was achieved in 53.2% of patients with a higher rate in the monotherapy group (64.7%, p = 0.001), and 30-day mortality was 26.1%. After adjustment, tigecycline monotherapy was not independently associated with clinical success or mortality. Sensitivity analyses excluding bloodstream and urinary tract infections showed consistent results.
CONCLUSION: In this real-world cohort of severely ill patients with MDR gram-negative infections, no outcome advantage was observed with tigecycline combination therapy after adjustment. Clinical outcomes were primarily driven by illness severity and infection characteristics rather than treatment strategy.
Предметные рубрики MeSH
HumansTigecyclineRetrospective StudiesAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialTreatment OutcomeFemaleGram-Negative Bacterial InfectionsMaleAgedAcinetobacter baumanniiMiddle AgedDrug Therapy, CombinationEscherichia coliKlebsiella pneumoniaeGram-Negative BacteriaAged, 80 and overAcinetobacter InfectionsAdultMicrobial Sensitivity Tests